# A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

> **NCT00624858** · PHASE2 · COMPLETED · sponsor: **Orexigen Therapeutics, Inc** · enrollment: 25 (estimated)

## Conditions studied

- Depression

## Interventions

- **DRUG:** naltrexone SR 32 mg/ bupropion SR 360 mg daily

## Key facts

- **NCT ID:** NCT00624858
- **Lead sponsor:** Orexigen Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2012-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624858, "A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00624858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*